Home > All News > Company News > Recombinant Human Growth Hormone for Injection

Recombinant Human Growth Hormone for Injection

Release Time:2018-12-14 Back to list

According to the literature, subcutaneous or intramuscular injection has the same effect. Subcutaneous injection usually brings higher serum GH concentration than intramuscular injection, but the concentration of IGF-1 is the same. GH uptake is usually slow, plasma GH concentration usually reaches its peak after 3-5 hours of administration, and clearance half-life is usually 2-3 hours; GH is cleared through liver and kidney, and adults are faster than children, and the untransferable GH directly excluded from urine is extremely small.
Indications: For the treatment of endogenous growth hormone deficiency, chronic renal failure and severe burns in children caused by Turner's syndrome.
Usage and dosage: Before use, add 1 ml of water for injection along the wall of the bottle slowly to freeze-dried rhGH, shake slightly to dissolve it completely, and do not shake violently.
The recommended dose is 0.1-0.15IU/kg body weight/day, once a day, subcutaneous injection for 3 months to 3 years, or as prescribed by doctors.
The recommended dose for severe burn treatment is 0.2-0.4 IU/kg body weight/day, once a day, subcutaneous injection, the course of treatment is generally about 2 weeks.
Side effects
Growth hormone can cause transient hyperglycemia, which usually returns to normal with the prolongation of medication time or after withdrawal.  About 1% of the short children in clinical trials had side effects, such as local transient reaction (pain, tingling, redness, etc.) at injection site and symptoms of fluid retention (peripheral edema, arthralgia or myalgia). These side effects occurred earlier, but the incidence of these side effects decreased with the time of medication and rarely affected daily activities.*  Long-term injection of recombinant human growth hormone (rhGH) causes antibody production in a few patients with low antibody binding capacity, which has no definite clinical significance. However, if the expected growth effect is not achieved, there may be antibody production, antibody binding force more than 2 mg/L, which may affect the efficacy.
1. Prohibited use in children with skeletal closure
2. Prohibition of use in patients with symptoms of cancer progression
3. Severe systemic infections and other critical patients should be banned during acute shock
Matters needing attention
1. Patients who are used for definite diagnosis under the guidance of doctors.
2. Diabetic patients may need to adjust the dosage of antidiabetic drugs.
3. For patients with growth hormone deficiency caused by brain tumors or with a history of intracranial injury, it is necessary to closely monitor the progress or recurrence of potential diseases.
4. Concurrent use of corticosteroids can inhibit the growth-promoting effect of growth hormone, so patients with ACTH deficiency should adjust the dosage of corticosteroids to avoid its inhibition on growth hormone production.
5. A few patients may have hypothyroidism in the course of growth hormone therapy. They should be corrected in time to avoid affecting the curative effect of growth hormone. They should be examined regularly for thyroid function and supplemented with thyroxine when necessary.
6. Patients with endocrine disorders (including growth hormone deficiency) may be prone to slippage of the epiphyseal plate of the femoral head. Should lameness occur during the treatment period of growth hormone, attention should be paid to evaluation.
7. Sometimes growth hormone can lead to excessive insulin status, so it is necessary to pay attention to whether patients have impaired glucose tolerance.
8. Avoid excessive use of drugs. A single injection of excessive growth hormone can lead to hypoglycemia, followed by hyperglycemia. Long-term excessive injection may lead to acromegaly symptoms and signs and other reactions related to excessive growth hormone.
9. The injection site should be changed frequently to prevent fat atrophy.